Differences in clinical efficacy between unfractionated heparin (UFH) and low molecular weight heparin (LMWH) but also between several LMWH preparations are a hot topic in research due to differences in study results: enoxaparin proved superiority over UFH (1,2), whereas dalteparin and nadroparin showed only equivalence (3,4). As there is a lack of trials directly comparing LMWHs, some investigators tried to answer the question for the most effective LMWH preparation with data from comparative meta-analysis: Montalescot et al. (5) published a post hoc analysis in JACC in which they postulated differences between dalteparin and enoxaparin concerning their action on circulating von Willebrand factor (vWf) levels in patients with unstable angina. This could be of clinical importance as vWf has been shown previously to be a predictor of outcome in acute coronary syndrome (6). However, in scrutinizing the analytical method in Montalescot's work, serious drawbacks are revealed.
